IHD therapeutics Flashcards
What is Chronic Coronary disease mean?
includes patients with/without angina, a history of revascularization and previous ACS
- NO MI or MI more than 12-30 months ago
- this lecture only focus on primary prevention (no previous ACS)
Is framingham risk score valid in patients with CCD?
No
- Stable angina was excluded
CCD is already at high risk
Does risk level in matter in terms of therapeutics for patients with CCD? What changes?
Therapeutics the same for all
- healthy interventions and mortality will change
The risk stratification for vessels, LV ejection fraction, stress induced, ECG findings show risk of how many years?
Soft/hard outcomes?
Annually
Hard outcomes only
Goal of therapy with angina
Reduce symptoms of angina
- cannot reduce the incidence of UA/MI or saves lives
Which interventions are for preventative therapies (lifesaving) (4)
- Antiplatelet therapy
- ACEi/ARB
- Statin
- Healthy behaviours
Which interventions are for antiaginal therapies?
Beta blockers
CCBs
Nitrates
PCI and CABG
Should ASA be given to patients with CCD?
Yes
When do we give clopidogrel
When ASA is not tolerable
What does the SAPAT trial tell us?
Group?
Intervention?
Patients with exertional chest pain
- no previous MI
- All on Sotalol (BB)
ASA reduce risk of MI & death by 34%
What did the ADAPTABLE trial tell us?
There is no additional benefit of higher dose ASA
- maybe more risk of GI haemorrhage
CAPRIE
Group?
Intervention?
Outcome?
over/under estimation?
Group
- Stroke, MI, symptomatic ASCV PAD
Intervention
- Clopidogrel 75mg vs ASA 325
RRR = 8.7%
- clopidogrel is technically more efficacious
Underestimation of results
- 0.33% of ASA vs 0.47% of intracranial haemorrhage
- if using ASA 81 the difference would be more
What did the CHARISMA trial tell us?
Group?
Intervention?
Outcome?
Group
- Primary group OR
- angina without event OR
- event was 12-30 months ago
Intervention
- Placebo + low dose ASA
- Clopidogrel + low dose ASA
Outcome:
- RR 0.93%
- no difference in primary prevention for dual anti platelet
COMPASS trial
Group
Intervention outcome
Group
- With or without diabetes
- Mix of primary and secondary prevention (previous MI)
- Most on ACE, BB, Statin
Comparison
- ASA + placebo vs ASA + rivaroxaban 2.5mg
Outcome:
- Can add low dose rivaroxaban if they are at high risk of stroke, & low-mod risk of bleed
What is the level A recommendation for ACE? for who?
For patients in CCD with
- HTN
- Diabetes
- LVEF less than 40%
- CKD
Can be considered if just have CCD (although not common to have that alone)
What are the benefits of ACE inhibitors? Benefits in low risk?
- hard outcomes
- revascularization
- mortality in high risk
Low risk patients have no sig benefit but reasonable to still give
RAAS natural effects
- inc BP
- inc Na/H2O retention
- inc wall tension
- Endothelial dysfunction
- inc clot formation
- myocardial fibrosis
Should you start with ACE or ARB? Are there differences?
No differences in the risk of stroke, IHD, and HF for each 5 mmHg reduction in BP
When assessed at zero BP reduction, the risk reduction for ACE was greater for IHD than ARBs
What is the level A recommendation for statin? For who?
All patients with CCD should be on a high-intensity statin
What should you add if patient on max-tolerated Statin + Ezetimibe with uncontrolled LDL or HDL:
PCSK9-inhibitor (-umab ending)
- Evolocumab
What are benefits of statins in IHD?
- reduce morbidity and mortality in IHD
- Help in plaque stabilization, even with patients in normal “LDL”
- improve endothelial function + anti-inflammatory effects
What is the target in adults with CCD who have hypertension?
Under 130/80
In adults with CCD, what are first line therapy to lower BP in those with elevated BP (120-129/<80 mmHg)
Nonpharms
Which non-pharm has the most reduction in BP?
Healthy diet
- DASH diet